Tracheobronchial Adenoid Cystic Carcinoma Treated Successfully With Chemoradiotherapy Followed by Durvalumab: A Case Report

• Published in: In vivo (Athens) Vol. 38; no. 3; pp. 1483 - 1488
• Main Authors: Nakatani, Y U, Kubota, Tetsuya, Hirakawa, Yoshiaki, Anayama, Takashi, Kimura, Tomoki, Yokoyama, Akihito
• Format: Journal Article
• Language: English
• Published: Greece International Institute of Anticancer Research 01.05.2024
• Subjects: Antibodies, Monoclonal - therapeutic use; Biopsy; Bronchial Neoplasms - drug therapy; Bronchial Neoplasms - pathology; Bronchial Neoplasms - therapy; Carcinoma, Adenoid Cystic - drug therapy; Carcinoma, Adenoid Cystic - pathology; Carcinoma, Adenoid Cystic - therapy; Chemoradiotherapy - methods; Humans; Male; Middle Aged; Tomography, X-Ray Computed; Tracheal Neoplasms - diagnosis; Tracheal Neoplasms - drug therapy; Tracheal Neoplasms - pathology; Tracheal Neoplasms - therapy; Treatment Outcome; paclitaxel; bronchus; durvalumab; trachea; carboplatin; chemoradiotherapy; Adenoid cystic carcinoma
• ISSN: 0258-851X; 1791-7549; 1791-7549
• DOI: 10.21873/invivo.13595

Tracheobronchial adenoid cystic carcinoma (ACC) is a rare type of malignancy. Although complete resection is standard treatment for localized ACC, treatment for unresectable ACC has not been established. It is unclear whether concurrent chemoradiotherapy (CCRT) followed by immune checkpoint inhibitor (ICI) therapy is effective for ACC. A 49-year-old man was admitted to our hospital for the treatment of dyspnea and thickening of the bronchial wall from the tracheal carina to the left main bronchus, as observed on a CT scan. Systemic examinations and transbronchial biopsy led to a diagnosis of locally advanced ACC. Although radiotherapy and chemotherapy are not regarded as very sensitive for ACC, a favorable response was obtained with CCRT. Following CCRT, he received ICI therapy with durvalumab for 1 year. The patient has remained in a stable condition 18 months after therapy, with no recurrence. ICI after CCRT might be a promising treatment option for unresectable tracheobronchial ACC.